BlackRock
CGEM icon

BlackRock’s Cullinan Oncology CGEM Stock Holding History

BlackRock’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63.2M Buy
4,449,966
+49,670
+1% +$638K ﹤0.01% 2363
2025
Q4 		$45.5M Buy
4,400,296
+230,334
+6% +$2.08M ﹤0.01% 2580
2025
Q3 		$24.7M Sell
4,169,962
-47,971
-1% -$351K ﹤0.01% 2958
2025
Q2 		$31.8M Sell
4,217,933
-2,929
-0.1% -$23.5K ﹤0.01% 2756
2025
Q1 		$32M Sell
4,220,862
-150,163
-3% -$1.44M ﹤0.01% 2642
2024
Q4 		$53.2M Buy
4,371,025
+32,300
+0.7% +$464K ﹤0.01% 2416
2024
Q3 		$72.6M Buy
4,338,725
+788,518
+22% +$14M ﹤0.01% 2260
2024
Q2 		$61.9M Buy
3,550,207
+1,121,214
+46% +$23.9M ﹤0.01% 2293
2024
Q1 		$41.4M Sell
2,428,993
-33,281
-1% -$514K ﹤0.01% 2551
2023
Q4 		$25.1M Buy
2,462,274
+225,989
+10% +$2M ﹤0.01% 2880
2023
Q3 		$20.2M Buy
2,236,285
+132,216
+6% +$1.38M ﹤0.01% 2934
2023
Q2 		$22.6M Sell
2,104,069
-151,528
-7% -$1.61M ﹤0.01% 2954
2023
Q1 		$23.1M Sell
2,255,597
-250,618
-10% -$2.76M ﹤0.01% 2905
2022
Q4 		$26.4M Buy
2,506,215
+131,390
+6% +$1.6M ﹤0.01% 2879
2022
Q3 		$30.4M Buy
2,374,825
+143,098
+6% +$1.93M ﹤0.01% 2788
2022
Q2 		$28.6M Buy
2,231,727
+405,558
+22% +$4.6M ﹤0.01% 2881
2022
Q1 		$19.1M Sell
1,826,169
-12,943
-0.7% -$175K ﹤0.01% 3197
2021
Q4 		$28.4M Buy
1,839,112
+209,518
+13% +$4.18M ﹤0.01% 3047
2021
Q3 		$36.8M Buy
1,629,594
+687,316
+73% +$18.4M ﹤0.01% 2867
2021
Q2 		$24.3M Buy
942,278
+54,470
+6% +$1.68M ﹤0.01% 3184
2021
Q1 		$37M Buy
+887,808
New +$36M ﹤0.01% 2820

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock's CGEM Position: Q1 2026 in Review

BlackRock increased its Cullinan Oncology (CGEM) stake by 1.1% in Q1 2026, buying an estimated $638K and bringing the position to 4,449,966 shares worth $63.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

BlackRock first reported a position in CGEM in Q1 2021 and has held it in 21 quarters since. The position peaked at $72.6M in Q3 2024. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • BlackRock held 4,449,966 shares of Cullinan Oncology worth $63.2M as of Q1 2026.
  • BlackRock bought 49,670 Cullinan Oncology shares in Q1 2026, an estimated $638K.
  • Cullinan Oncology made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2363 holding.
  • BlackRock first reported a position in Cullinan Oncology in Q1 2021 and has held it in 21 quarters since.
  • BlackRock's Cullinan Oncology position peaked at $72.6M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.